Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dupilumab for Eosinophilic Esophagitis With Severe Strictures (DESTRICT Study)

NCT06352073 is registered in ClinicalTrials.gov with University of North Carolina, Chapel Hill as lead sponsor.

NCT NCT06352073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06352073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dupilumab for Eosinophilic Esophagitis With Severe Strictures (DESTRICT Study)
Lead sponsor
University of North Carolina, Chapel Hill
Phase
Phase 4
Overall status
Active, not recruiting
Start date
May 16, 2024
Completion date
December 31, 2026
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

eoe, eosinophilic esophagitis